 GAITHERSBURG, Md., Jan. 13, 2021 GLOBE NEWSWIRE -- OpGen, Inc. Nasdaq: OPGN, OpGen, a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease, announced today that total pro-forma preliminary unaudited revenue including revenue from discontinued operations for OpGen in 2020 was approximately 5.2 million, compared to about 6.0 million in 2019. Fourth quarter 2020 revenue for OpGen was approximately 1.3 million compared to 0.8 million in Q4-2019. The company expects to provide fourth quarter 2020 and full year 2020 financial results during its upcoming earnings call in March 2021. OpGens cash position as of December 31, 2020 was approximately 13.3 million, an increase from 2.7 million in 2019. 